The legal inquiry focuses on whether the leadership at the NASDAQ-listed biotechnology company prioritized personal interests over those of the shareholders. Justin Kuehn, the attorney heading the investigation, has invited long-term stockholders to come forward to discuss potential litigation. The firm operates on a contingency basis, meaning they cover all case costs without charging investor clients for consultations or representation. Given the potential for strict filing deadlines in derivative litigation, the firm is urging interested parties to reach out immediately to preserve their legal rights. This move aims to address claims of corporate misconduct and seeks to restore accountability within the company’s decision-making structure.